Immune Therapy for Cancer

被引:500
作者
Dougan, Michael [1 ]
Dranoff, Glenn
机构
[1] Brigham & Womens Hosp, Dept Med Oncol, Boston, MA 02115 USA
关键词
monoclonal (antibody); inflammation; vaccine; adjuvants; immunotherapy; REGULATORY T-CELLS; COLONY-STIMULATING FACTOR; GROWTH-FACTOR RECEPTOR; BACILLUS-CALMETTE-GUERIN; TUMOR-NECROSIS-FACTOR; PHASE-III TRIAL; NONSTEROIDAL ANTIINFLAMMATORY DRUGS; LYMPHOCYTE-ASSOCIATED ANTIGEN-4; HELICOBACTER-PYLORI INFECTION; METASTATIC BREAST-CANCER;
D O I
10.1146/annurev.immunol.021908.132544
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Over the past decade, immune therapy has become a standard treatment for a variety of cancers. Monoclonal antibodies, immune adjuvants, and vaccines against oncogenic viruses are now well-established cancer therapies. Immune modulation is a principal element of supportive care for many high-dose chemotherapy regimens. In addition, immune activation is now appreciated as central to the therapeutic mechanism of bone marrow transplantation for hematologic malignancies. Advances in our understanding of the molecular interactions between tumors and the immune system have led to many novel investigational therapies and continue to inform efforts for devising more potent therapeutics. Novel approaches to immune-based cancer treatment strive to augment antitumor immune responses by expanding tumor-reactive T cells, providing exogenous immune-activating stimuli, and antagonizing regulatory pathways that induce immune tolerance. The future of immune therapy for cancer is likely to combine many of these approaches to generate more effective treatments.
引用
收藏
页码:83 / 117
页数:35
相关论文
共 239 条
[91]   Epstein-Barr virus-associated malignancies: epidemiologic patterns and etiologic implications [J].
Hsu, JL ;
Glaser, SL .
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2000, 34 (01) :27-53
[92]   Drug therapy: Trastuzumab - Mechanism of action and use in clinical practice [J].
Hudis, Clifford A. .
NEW ENGLAND JOURNAL OF MEDICINE, 2007, 357 (01) :39-51
[93]   CpG DNA activation and plasma-cell differentiation of CD27- naive human B cells [J].
Huggins, Jennifer ;
Pellegrin, Tina ;
Felgar, Raymond E. ;
Wei, Chungwen ;
Brown, Miguel ;
Zheng, Bo ;
Milner, Eric C. B. ;
Bernstein, Steven H. ;
Sanz, Ignacio ;
Zand, Martin S. .
BLOOD, 2007, 109 (04) :1611-1619
[94]   Treatment of metastatic melanoma with autologous CD4+T cells against NY-ESO-1 [J].
Hunder, Naomi N. ;
Wallen, Herschel ;
Cao, Jianhong ;
Hendricks, Deborah W. ;
Reilly, John Z. ;
Rodmyre, Rebecca ;
Jungbluth, Achim ;
Gnjatic, Sacha ;
Thompson, John A. ;
Yee, Cassian .
NEW ENGLAND JOURNAL OF MEDICINE, 2008, 358 (25) :2698-2703
[95]   Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer [J].
Hurwitz, H ;
Fehrenbacher, L ;
Novotny, W ;
Cartwright, T ;
Hainsworth, J ;
Heim, W ;
Berlin, J ;
Baron, A ;
Griffing, S ;
Holmgren, E ;
Ferrara, N ;
Fyfe, G ;
Rogers, B ;
Ross, R ;
Kabbinavar, F .
NEW ENGLAND JOURNAL OF MEDICINE, 2004, 350 (23) :2335-2342
[96]   Engineered antibodies with increased activity to recruit complement [J].
Idusogie, EE ;
Wong, PY ;
Presta, LG ;
Gazzano-Santoro, H ;
Totpal, K ;
Ultsch, M ;
Mulkerrin, MG .
JOURNAL OF IMMUNOLOGY, 2001, 166 (04) :2571-2575
[97]   Unique chemotactic response profile and specific expression of chemokine receptors CCR4 and CCR8 by CD4+CD25+ regulatory T cells [J].
Iellem, A ;
Mariani, M ;
Lang, R ;
Recalde, H ;
Panina-Bordignon, P ;
Simigaglia, F ;
D'Ambrosio, D .
JOURNAL OF EXPERIMENTAL MEDICINE, 2001, 194 (06) :847-853
[98]   Prevention of gastrointentional tumors based on adenomatous polyposis coli gene mutation by dendrite cell vaccine [J].
Iinuma, T ;
Homma, S ;
Noda, T ;
Kufe, D ;
Ohno, T ;
Toda, G .
JOURNAL OF CLINICAL INVESTIGATION, 2004, 113 (09) :1307-1317
[99]   A phase I study of α-galactosylceramide (KRN7000)-pulsed dendritic cells in patients with advanced and recurrent non-small cell lung cancer [J].
Ishikawa, A ;
Motohashi, S ;
Ishikawa, E ;
Fuchida, H ;
Higashino, K ;
Otsuji, M ;
Iizasa, T ;
Nakayama, T ;
Taniguchi, M ;
Fujisawa, T .
CLINICAL CANCER RESEARCH, 2005, 11 (05) :1910-1917
[100]   Toll-like receptor control of the adaptive immune responses [J].
Iwasaki, A ;
Medzhitov, R .
NATURE IMMUNOLOGY, 2004, 5 (10) :987-995